Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9213IDB
  • |
  • Pages: 187
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2017, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS) or keratitis sicca, is a multifactorial disease of the tears and the ocular surface that results in discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. Symptoms include eye fatigue, sensitivity to light, eye redness and stringy mucus in or around eyes. Risk factors include age, having laser eye surgery and taking medications that can cause dry eyes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 21, 11, 1, 19, 5 and 1 respectively.

Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Keratoconjunctivitis sicca (Dry Eye)-Overview 8

Keratoconjunctivitis sicca (Dry Eye)-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Products under Development by Companies 14

Keratoconjunctivitis sicca (Dry Eye)-Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Keratoconjunctivitis sicca (Dry Eye)-Companies Involved in Therapeutics Development 28

Aldeyra Therapeutics Inc 28

Allergan Plc 28

Ascendia Pharmaceuticals LLC 29

BioLineRx Ltd 29

Cambium Medical Technologies LLC 30

Chong Kun Dang Pharmaceutical Corp 30

Dompe Farmaceutici SpA 31

Elasmogen Ltd 31

HanAll Biopharma Co Ltd 32

Herantis Pharma Plc 32

Huons Co Ltd 33

InSite Vision Inc 33

Kala Pharmaceuticals Inc 34

KPI Therapeutics Inc 34

Kukje Pharmaceutical Industry Co Ltd 35

Laboratoires Thea SA 35

Lipicard Technologies Ltd 36

Merck & Co Inc 36

Mimetogen Pharmaceuticals Inc 37

Mitotech SA 37

Nanomerics Ltd 38

Nemus Bioscience Inc 38

Neuroptis Biotech 39

Novaliq GmbH 39

Ocular Therapeutix Inc 40

Oculis ehf 40

OncoNOx ApS 41

Otsuka Holdings Co Ltd 41

Parion Sciences Inc 42

Quorum Innovations LLC 42

RegeneRx Biopharmaceuticals Inc 43

Samjin Pharmaceutical Co Ltd 43

Santen Pharmaceutical Co Ltd 44

Seikagaku Corp 44

Shire Plc 45

Sun Pharmaceutical Industries Ltd 45

TearSolutions LLC 46

TopiVert Ltd 46

Vanda Pharmaceuticals Inc 47

Xigen SA 47

Keratoconjunctivitis sicca (Dry Eye)-Drug Profiles 48

ADX-102-Drug Profile 48

ADX-103-Drug Profile 53

AGN-195263-Drug Profile 54

AGN-223575-Drug Profile 55

AGN-232411-Drug Profile 56

AL-41A1-Drug Profile 57

Androgen Tears-Drug Profile 58

AVA-3486-Drug Profile 59

AVX-012-Drug Profile 60

AX-1606-Drug Profile 61

BL-1230-Drug Profile 62

BRM-421-Drug Profile 63

cenegermin-Drug Profile 64

cinhyaluronate sodium-Drug Profile 67

Cis-Urocanic Acid-Drug Profile 68

cyclosporine-Drug Profile 70

cyclosporine-Drug Profile 73

cyclosporine-Drug Profile 75

cyclosporine-Drug Profile 76

cyclosporine-Drug Profile 77

cyclosporine-Drug Profile 78

cyclosporine-Drug Profile 79

cyclosporine SR-Drug Profile 80

dexamethasone acetate SR-Drug Profile 81

diclofenac sodium-Drug Profile 87

diquafosol tetrasodium-Drug Profile 88

Drug for Dry Eye-Drug Profile 90

Drugs to Agonize FPR2 for Dry Eye-Drug Profile 91

Elate Ocular-Drug Profile 92

ELN-22-Drug Profile 93

HL-036-Drug Profile 94

HU-007-Drug Profile 95

hyaluronate sodium-Drug Profile 96

ISV-101-Drug Profile 97

K-089-Drug Profile 98

KeraKlear-Drug Profile 99

KJ-14003-Drug Profile 100

KJ-16001-Drug Profile 101

KL-7016-Drug Profile 102

KPI-190-Drug Profile 103

Lacripep-Drug Profile 104

Leukothera-Drug Profile 105

lifitegrast-Drug Profile 107

LME-636-Drug Profile 111

loteprednol etabonate-Drug Profile 112

LT-4002-Drug Profile 115

LT-4003-Drug Profile 116

NB-2222-Drug Profile 117

NOP-3-Drug Profile 118

NOP-5-Drug Profile 119

Nov-03-Drug Profile 120

OC-301-Drug Profile 121

OTX-101-Drug Profile 122

OX-1001-Drug Profile 124

P-321-Drug Profile 125

plastoquinone decyl triphenylphosphonium bromide-Drug Profile 127

PPL-003-Drug Profile 129

Protearin-Drug Profile 131

Qi-401-Drug Profile 132

rebamipide-Drug Profile 133

RGN-259-Drug Profile 135

RP-101-Drug Profile 142

SA-001-Drug Profile 143

SJP-002-Drug Profile 144

Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye-Drug Profile 145

solithromycin-Drug Profile 146

ST-266-Drug Profile 160

tadekinig alfa-Drug Profile 162

tavilermide hydrochloride-Drug Profile 163

TOP-1630-Drug Profile 165

XG-104-Drug Profile 166

zucapsaicin-Drug Profile 167

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects 169

Keratoconjunctivitis sicca (Dry Eye)-Discontinued Products 173

Keratoconjunctivitis sicca (Dry Eye)-Product Development Milestones 174

Featured News & Press Releases 174

Appendix 181

Methodology 181

Coverage 181

Secondary Research 181

Primary Research 181

Expert Panel Validation 181

Contact Us 181

Disclaimer 182

List of Figures

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Aldeyra Therapeutics Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Allergan Plc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Ascendia Pharmaceuticals LLC, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by BioLineRx Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Cambium Medical Technologies LLC, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Dompe Farmaceutici SpA, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Elasmogen Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by HanAll Biopharma Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Herantis Pharma Plc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Huons Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by InSite Vision Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kala Pharmaceuticals Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by KPI Therapeutics Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Laboratoires Thea SA, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Lipicard Technologies Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Merck & Co Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Mimetogen Pharmaceuticals Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Mitotech SA, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Nanomerics Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Nemus Bioscience Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Neuroptis Biotech, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Novaliq GmbH, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Ocular Therapeutix Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Oculis ehf, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by OncoNOx ApS, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Otsuka Holdings Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Parion Sciences Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Quorum Innovations LLC, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Santen Pharmaceutical Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Seikagaku Corp, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Shire Plc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Sun Pharmaceutical Industries Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by TearSolutions LLC, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by TopiVert Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Vanda Pharmaceuticals Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Xigen SA, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H1 2017 (Contd..2), H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H1 2017 (Contd..3), H1 2017

Keratoconjunctivitis sicca (Dry Eye)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aldeyra Therapeutics Inc, Allergan Plc, Ascendia Pharmaceuticals LLC, BioLineRx Ltd, Cambium Medical Technologies LLC, Chong Kun Dang Pharmaceutical Corp, Dompe Farmaceutici SpA, Elasmogen Ltd, HanAll Biopharma Co Ltd, Herantis Pharma Plc, Huons Co Ltd, InSite Vision Inc, Kala Pharmaceuticals Inc, KPI Therapeutics Inc, Kukje Pharmaceutical Industry Co Ltd, Laboratoires Thea SA, Lipicard Technologies Ltd, Merck & Co Inc, Mimetogen Pharmaceuticals Inc, Mitotech SA, Nanomerics Ltd, Nemus Bioscience Inc, Neuroptis Biotech, Novaliq GmbH, Ocular Therapeutix Inc, Oculis ehf, OncoNOx ApS, Otsuka Holdings Co Ltd, Parion Sciences Inc, Quorum Innovations LLC, RegeneRx Biopharmaceuticals Inc, Samjin Pharmaceutical Co Ltd, Santen Pharmaceutical Co Ltd, Seikagaku Corp, Shire Plc, Sun Pharmaceutical Industries Ltd, TearSolutions LLC, TopiVert Ltd, Vanda Pharmaceuticals Inc, Xigen SA

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com